A cross-sector expert panel to improve patient access to innovative cancer medicines in the UK recommended that drug prices should be tied to the benefits they deliver. In addition, they recommend that in cases where one drug treats many conditions, different prices should be charged for the drug according to the medical condition being treated. Such an approach would make it possible for companies to reduce the price of a drug for a certain disease without having to do so across the board or where it would otherwise not be cost-effective. Read more here.
(Source: Vibha Sharma; Pink Sheet; 11/10/20)